Cargando…
An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system leading to demyelination and neurodegeneration of brain tissue. For a long time, research focused on T cells as the primary mechanism of disease. Driven by reports on the clinical results of B cell-depleting ther...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Vienna
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208251/ https://www.ncbi.nlm.nih.gov/pubmed/35723820 http://dx.doi.org/10.1007/s10354-022-00939-w |